inclusion criteria: 1. laboratory confirmed sars-cov-2 infection by rt-pcr or positive antigenic test 2. asymptomatic or mild to moderate covid-19 (who progression scale \<5). patients receiving oxygen therapy for reasons other than a pulmonary covid-19 are eligible) 3. ≥ 16 years of age; 4. immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) * severe immunosuppression (e.g., hiv infection with cd4 + t cell count \<350 / µl) * neutropenia (\<1000 neutrophils / µl) ≥1 week * lymphocytopenia (\<200 lymphocytes/µl) * hereditary immunodeficiencies * intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, everolimus, mtor inhibitors etc.) in the last 12 months * active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib * aggressive lymphomas (all types) * acute lymphatic leukemia * acute myeloid leukemia * acute promyelocytic leukemia * t prolymphocytic leukemia * primary central nervous system lymphoma * stem cell transplantation * light chain amyloidosis * chronic lymphoid leukemia * multiple myeloma * sickle cell disease * bone marrow transplant * organ transplant * being on the waiting list for an organ transplant 5. willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) 6. enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) or holders of health insurance 7. participant's or its legal representative's signature of the informed consent form

inclusion criteria: 1. laboratory confirmed sars-cov-2 infection by rt-pcr or positive antigenic test 2. asymptomatic or mild to moderate covid-19 (who progression scale \<5). patients receiving oxygen therapy for reasons other than a pulmonary covid-19 are eligible) 3. ≥ 16 years of age; 4. immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) * severe immunosuppression (e.g., hiv infection with cd4 + t cell count \<350 / µl) * neutropenia (\<1000 neutrophils / µl) ≥1 week * lymphocytopenia (\<200 lymphocytes/µl) * hereditary immunodeficiencies * intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, everolimus, mtor inhibitors etc.) in the last 12 months * active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib * aggressive lymphomas (all types) * acute lymphatic leukemia * acute myeloid leukemia * acute promyelocytic leukemia * t prolymphocytic leukemia * primary central nervous system lymphoma * stem cell transplantation * light chain amyloidosis * chronic lymphoid leukemia * multiple myeloma * sickle cell disease * bone marrow transplant * organ transplant * being on the waiting list for an organ transplant 5. willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) 6. enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) or holders of health insurance 7. participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr or positive antigenic test asymptomatic or mild to moderate covid-19 (who progression scale <5). patients receiving oxygen therapy for reasons other than a pulmonary covid-19 are eligible) ≥ 16 years of age; immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) severe immunosuppression (e.g., hiv infection with cd4 + t cell count <350 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, everolimus, mtor inhibitors etc.) in the last 12 months active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) or holders of health insurance participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr or positive antigenic test asymptomatic or mild to moderate covid-19 (who progression scale <5). patients receiving oxygen therapy for reasons other than a pulmonary covid-19 are eligible) ≥ 16 years of age; immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) severe immunosuppression (e.g., hiv infection with cd4 + t cell count <350 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, everolimus, mtor inhibitors etc.) in the last 12 months active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) or holders of health insurance participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr asymptomatic or mild to moderate covid-19 (who progression scale ≤5) ≥ 16 years of age; body weight > 40 kg immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) severe immunosuppression (e.g., hiv infection with cd4 + t cell count <200 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) in the last 12 months aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr asymptomatic or mild to moderate covid-19 (who progression scale ≤5) ≥ 16 years of age; body weight > 40 kg immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) severe immunosuppression (e.g., hiv infection with cd4 + t cell count <200 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) in the last 12 months aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr asymptomatic or mild to moderate covid-19 (who progression scale ≤5) ≥ 16 years of age; body weight > 40 kg immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) 53 severe immunosuppression (e.g., hiv infection with cd4 + t cell count <200 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisolone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) in the last 12 months aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) participant's or its legal representative's signature of the informed consent form

inclusion criteria: laboratory confirmed sars-cov-2 infection by rt-pcr asymptomatic or mild to moderate covid-19 (who progression scale ≤5) ≥ 16 years of age; body weight > 40 kg immunocompromised as defined by ≥ 1 risk factors for severe covid-19 as assessed by the foph list (criteria 5: diseases/treatments leading to immune suppression) 53 severe immunosuppression (e.g., hiv infection with cd4 + t cell count <200 / µl) neutropenia (<1000 neutrophils / µl) ≥1 week lymphocytopenia (<200 lymphocytes/µl) hereditary immunodeficiencies intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisolone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) in the last 12 months aggressive lymphomas (all types) acute lymphatic leukemia acute myeloid leukemia acute promyelocytic leukemia t prolymphocytic leukemia primary central nervous system lymphoma stem cell transplantation light chain amyloidosis chronic lymphoid leukemia multiple myeloma sickle cell disease bone marrow transplant organ transplant being on the waiting list for an organ transplant willing and able to comply with study requirements and restrictions as described in the informed consent form (icf) enrolled in or a beneficiary of a social security program (state medical aid (ame) is not a social security program) participant's or its legal representative's signature of the informed consent form